Brief: Sienna Biopharmaceuticals-Expects To Report Results From 3 Pivotal Trials With SNA-001 In Late Jan/Early Feb 2019-SEC Filing
12/12/2018 14:33
Dec 12 (Reuters) - Sienna Biopharmaceuticals Inc SNNA.O :
* SIENNA BIOPHARMACEUTICALS - EXPECTS TO REPORT RESULTS FROM
3
PIVOTAL TRIALS WITH SNA-001 IN LATE JAN/EARLY FEB 2019 - SEC
FILING
Source text for Eikon: http://bit.ly/2QprRNc
Further company coverage: SNNA.O
Recent news on Sienna Biopharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Adobe, Oracle, Snap, Phreesia, Sarepta, Aquestive Therapeutics, Patterson-UTI
U.S. STOCKS ON THE MOVE-Lululemon, GE, Starbucks, Delta Air Lines, Lumber Liquidators, Lovesac
Sienna Biopharma: Falls on Nasdaq delisting plans
Brief: Sienna Biopharma Says Bankruptcy Court Approved Sale Of Assets Related To SNA-001 For $1.7 Mln In Cash
Brief: Sienna Biopharmaceuticals Announces Court Approval Of Chapter 11 Bidding Procedures